Pulmonary Function Test as a Diagnostic Tool for Post-COVID-19 Effects
Authors:
Open Access
- 7 February 2023
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 15 (2) , e34751
Abstract
COVID-19-infected survivors are reporting persistent anomalies upon hospital discharge. After one year, a sizable percentage of COVID-19 survivors still have persistent symptoms affecting different bodily systems. Evidence suggests that the lungs are the most affected organs by COVID-19. It may also cause corollary and other medical issues. The literature on preceding COVID-19 infections reviews that patients may also experience chronic impairment in breathing characteristics after discharge. The outcome of COVID-19 may remain for weeks to months after the initial recovery. Our goal is to determine the superiority of the restrictive pattern, obstructive pattern, and adjusted diffusion in patients post-COVID-19 contamination and to explain the distinctive opinions of breathing characteristics used with those patients. Therefore, lung function tests were measured post-discharge for three to 12 months. According to estimates, 80% of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-infected patients experienced one or more chronic symptoms. Multidisciplinary teams are required to develop preventive measures, rehabilitation methods, and scientific control plans with a completely patient-centered attitude for long-term COVID-19 care. Clarifying the pathophysiologic mechanisms, creating and testing specific interventions, and treating patients with long-term COVID-19 are urgently needed. The goal of this review is to locate research evaluating COVID-19's long-term effects. A person who has suffered from COVID-19 in the past showed changes in their pulmonary function test. So, we have to notice the changes and recovery from post-COVID-19 effects. COVID-19 survivors were observed in an eventual observational study and continuously examined three, six, and 12 months after having COVID-19 infections. We evaluated the clinical features and concentrations of circulating pulmonary epithelial and endothelial markers in COVID-19 survivors with normal or lower diffusion capacity for carbon monoxide (DLCO) six months after discharge to analyze risk factors and underlying pathophysiology.Keywords
This publication has 36 references indexed in Scilit:
- Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19Cochrane Database of Systematic Reviews, 2021
- A Follow-Up Study of Lung Function and Chest Computed Tomography at 6 Months after Discharge in Patients with Coronavirus Disease 2019Canadian Respiratory Journal, 2021
- Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of lifeEuropean Respiratory Journal, 2021
- Comprehensive Health Assessment 3 Months After Recovery From Acute Coronavirus Disease 2019 (COVID-19)Clinical Infectious Diseases, 2020
- Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recoveryeClinicalMedicine, 2020
- Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus‐2 disease: COVID‐19Drug Development Research, 2020
- Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluationJournal of Medical Virology, 2020
- Three-Month Follow-Up Study of Survivors of Coronavirus Disease 2019 after DischargeJournal of Korean Medical Science, 2020
- Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysisJournal of Rehabilitation Medicine, 2020
- 6-minute walking test: a useful tool in the management of heart failure patientsTherapeutic Advances in Cardiovascular Disease, 2019